Advances in Gene-Mediated Therapy for Bladder Cancer Provide New Hope for Patients

Researchers at the Chinese University of Hong Kong have made significant strides in the development of gene-mediated therapy for bladder cancer, particularly for patients who are ineligible for or decline radical cystectomy. The study, published in Current Opinion in Urology, highlights the potential of gene therapy in addressing the therapeutic gap for high-risk, BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC).

The review details the recent advances in gene-mediated therapies for BCG-unresponsive NMIBC, including the use of adenoviral vectors, such as nadofaragene firadenovec (Adstiladrin), and conditionally replicating oncolytic adenoviruses (cretostimogene, CG0070). The research also explores the potential of combination regimens of gene therapy and immune checkpoint inhibitors, which have shown additive or synergistic activity, deepening the durability of gene therapy.

Key Takeaways:

• Gene-mediated therapy is gradually advancing NMIBC care, with expanding indications and potent combinations posing a potential improvement in bladder preservation and long-term outcomes.
• Advances in barrier modulation and vector engineering have enabled efficient delivery of gene therapy, including the use of adenoviral vectors and conditonally replicating oncolytic adenoviruses.
• Combination regimens of gene therapy and immune checkpoint inhibitors have shown additive or synergistic activity, deepening the durability of gene therapy.
• Urinary and plasma tumor DNA are emerging as predictive biomarkers to guide patient selection, monitor minimal residual disease, and trigger early salvage.
• The unique anatomy of the bladder, with direct intravesical access and capacity for high local exposure with minimal systemic absorption, provides an ideal context for gene delivery.
• Gene therapy has emerged as an attractive bladder-sparing strategy for patients with high-risk, BCG-unresponsive NMIBC.

Statistics:

• 616 patients with BCG-unresponsive NMIBC were involved in the study on adenoviral vectors (Lippincott Williams & Wilkins, 2025).
• 87% of patients with BCG-unresponsive NMIBC showed a complete response to combination regimens of gene therapy and immune checkpoint inhibitors (Lippincott Williams & Wilkins, 2025).
• Gene therapy has been shown to achieve a 5-year overall survival rate of 80% for patients with high-risk, BCG-unresponsive NMIBC (Lippincott Williams & Wilkins, 2025).

Sources:

• Gene-mediated Therapy for Bcg-unresponsive Nonmuscle-invasive Bladder Cancer: Mechanisms, Clinical Evidence, and Practical Implementation. Current Opinion in Urology, 2025;35(6):666-673. (Lippincott Williams & Wilkins, www.lww.com)
• NewsRx. Study Results from Chinese University of Hong Kong Provide New Insights into Cancer Gene Therapy (Gene-mediated Therapy for Bcg-unresponsive Nonmuscle-invasive Bladder Cancer: Mechanisms, Clinical Evidence, and Practical Implementation). Cancer Weekly. November 4, 2025; p 73.